Thus, both the status of MIG6 expression and ERFFI1 mutations could serve as additional biomarkers, alongside well‐established EGFR mutation status, to select patients who may benefit from EGFR‐targeted cancer therapy, particularly in cases where known oncogenic EGFR mutations are absent. The gene discussed is EGFR; the disease is cancer.